Prostate-specific antigen and long-term prediction of prostate cancer incidence and mortality in the general population

European Urology

Volumn 61, Issue 5, 2012, Pages 865-874

  Ørsted, David D ^a,b   Nordestgaard, Børge G ^a,b,c   Jensen, Gorm B ^c   Schnohr, Peter ^c   Bojesen, Stig E ^a,b,c  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c BISPEBJERG HOSPITAL   (Denmark)

Author keywords

Baseline prostate specific antigen; General population; Prostate cancer incidence and mortality

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT;

ADULT; AGED; AGED, 80 AND OVER; DENMARK; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK; YOUNG ADULT;

EID: 84859428170     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2011.11.007     Document Type: Article

References (34)

1. D.M. Parkin, F. Bray, J. Ferlay, and P. Pisani Global cancer statistics, 2002 CA Cancer J Clin 55 2005 74 108 (Pubitemid 40372904)
2. A. Jemal, R. Siegel, and E. Ward Cancer statistics, 2009 CA Cancer J Clin 59 2009 225 249
3. S.P. Balk, Y.J. Ko, and G.J. Bubley Biology of prostate-specific antigen J Clin Oncol 21 2003 383 391 (Pubitemid 46606169)
4. J. Fang, E.J. Metter, and P. Landis Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging Urology 58 2001 411 416 (Pubitemid 32816360)
5. P.H. Gann, C.H. Hennekens, and M.J. Stampfer A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer JAMA 273 1995 289 294
6. S. Loeb, K.A. Roehl, and J.A. Antenor Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old Urology 67 2006 316 320 (Pubitemid 43189848)
7. D. Connolly, A. Black, A. Gavin, P.F. Keane, and L.J. Murray Baseline prostate-specific antigen level and risk of prostate cancer and prostate-specific mortality: diagnosis is dependent on the intensity of investigation Cancer Epidemiol Biomarkers Prev 17 2008 271 278 (Pubitemid 351272775)
8. P. Tang, L. Sun, and M.A. Uhlman Baseline PSA as a predictor of prostate cancer-specific mortality over the past 2 decades: Duke University experience Cancer 116 2010 4711 4717
9. A.J. Vickers, A.M. Cronin, and T. Bjork Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study BMJ 341 2010 4521 4529
10. H. Lilja, D. Ulmert, and T. Bjork Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years J Clin Oncol 25 2007 431 436 (Pubitemid 350002992)
11. H. Lilja, A.M. Cronin, and A. Dahlin Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50 Cancer 117 2011 1210 1219
12. K.H. Allin, S.E. Bojesen, and B.G. Nordestgaard Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer J Clin Oncol 27 2009 2217 2224
13. D.D. Orsted, S.E. Bojesen, A. Tybjaerg-Hansen, and B.G. Nordestgaard Tumor suppressor p53 Arg72Pro polymorphism and longevity, cancer survival, and risk of cancer in the general population J Exp Med 204 2007 1295 1301 (Pubitemid 46919867)
14. J. Zacho, A. Tybjaerg-Hansen, and J.S. Jensen Genetically elevated C-reactive protein and ischemic vascular disease N Engl J Med 359 2008 1897 1908
15. S.E. Bojesen, A. Tybjaerg-Hansen, and B.G. Nordestgaard Integrin beta3 Leu33Pro homozygosity and risk of cancer J Natl Cancer Inst 95 2003 1150 1157 (Pubitemid 37045393)
16. T.O. Mukai, F. Bro, K.V. Pedersen, and P. Vedsted Use of prostate-specific antigen testing [in Danish] Ugeskr Laeger 172 2010 696 700
17. H.H. Storm, E.V. Michelsen, I.H. Clemmensen, and J. Pihl The Danish Cancer Registry - history, content, quality and use Dan Med Bull 44 1997 535 539
18. K. Juel, and K. Helweg-Larsen The Danish registers of causes of death Dan Med Bull 46 1999 354 357 (Pubitemid 29439149)
19. J.P. Fine, and R.J. Gray A proportional hazards model for the subdistribution of a competing risk J Am Stat Assoc 94 1999 496 509
20. K. Juul, A. Tybjaerg-Hansen, P. Schnohr, and B.G. Nordestgaard Factor V Leiden and the risk for venous thromboembolism in the adult Danish population Ann Intern Med 140 2004 330 337
21. P. Pal, H. Xi, and G. Sun Tagging SNPs in the kallikrein genes 3 and 2 on 19q13 and their associations with prostate cancer in men of European origin Hum Genet 122 2007 251 259 (Pubitemid 47616533)
22. G.L. Andriole, E.D. Crawford, and R.L. Grubb III Mortality results from a randomized prostate-cancer screening trial N Engl J Med 360 2009 1310 1319
23. F.H. Schroder, J. Hugosson, and M.J. Roobol Screening and prostate-cancer mortality in a randomized European study N Engl J Med 360 2009 1320 1328
24. D. Ulmert, A.M. Cronin, and T. Bjork Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study BMC Med 6 2008 6
25. O.W. Brawley Prostate cancer screening; is this a teachable moment? J Natl Cancer Inst 101 2009 1295 1297
26. H.G. Welch, and P.C. Albertsen Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005 J Natl Cancer Inst 101 2009 1325 1329
27. P.R. Carroll, J.M. Whitson, and M.R. Cooperberg Serum prostate-specific antigen for the early detection of prostate cancer: always, never, or only sometimes? J Clin Oncol 29 2011 345 347
28. S. Loeb, H.B. Carter, W.J. Catalona, J.W. Moul, and F.H. Schroder Baseline prostate-specific antigen testing at a young age Eur Urol 61 2012 1 7
29. Chou R, Croswell JM, Dana T, et al. Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. In press.
30. H.B. Carter, J.I. Epstein, D.W. Chan, J.L. Fozard, and J.D. Pearson Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer JAMA 277 1997 1456 1460 (Pubitemid 27208888)
31. K. Ito, T. Yamamoto, and M. Ohi Possibility of re-screening intervals of more than one year in men with PSA levels of 4.0 ng/ml or less Prostate 57 2003 8 13 (Pubitemid 37070144)
32. M.J. Roobol, D.W. Roobol, and F.H. Schroder Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam) Urology 65 2005 343 346 (Pubitemid 40248025)
33. P.C. Albertsen, D.F. Moore, and W. Shih Impact of comorbidity on survival among men with localized prostate cancer J Clin Oncol 29 2011 1335 1341
34. D.D. Ørsted, S.E. Bojesen, S.F. Nielsen, and B.G. Nordestgaard Association of clinical benign prostate hyperplasia with prostate cancer incidence and mortality revisited: a nationwide cohort study of 3 009 258 men Eur Urol 60 2011 691 698